Skip to Main Content

Young Choi, MD

Professor Emeritus of Pathology
DownloadHi-Res Photo

Additional Titles

Director, Bridgeport Hospital Clinical Laboratories

About

Titles

Professor Emeritus of Pathology

Director, Bridgeport Hospital Clinical Laboratories

Biography

I have developed and provided a full aspects of pathology and lab medicine at the Bridgeport Hospital for the last 17 years. I have contributed a quality of patient care in the community. I will continue to pursue my career in pathology and lab medicine and continue my research interest.

Appointments

Other Departments & Organizations

Education & Training

Resident
State University of New York (1972)
Resident
Boston City Hospital - Mallory Institute of Pathology (1970)
Fellow
Memorial Sloan Kettering Cancer Center (1969)
Resident
New York Hospital-Cornell Medical College (1968)
MD
Seoul National University (1966)

Board Certifications

  • Cytopathology

    Certification Organization
    AB of Pathology
    Original Certification Date
    1991
  • Immunopathology

    Certification Organization
    AB of Pathology
    Original Certification Date
    1984
  • Anatamic & Clinical Pathology

    Certification Organization
    AB of Pathology
    Original Certification Date
    1972

Research

Overview

Currently, ERa is the main therapeutic and prognostic marker for breast cancer but about 30% do not respond to the antiestrogens. Some studies have shown that ERb isoforms are predictive marker to antiestrogens. ERb isoforms also are significantly expressed in ERa negative tumors. Thus, ERb may be the potential targeted therapy in some ERa and ERa negative breast cancers. ERb isoforms mRNA by qPCR and protein expression by immunohistochemistry will be tested in both ERa positive and ERa negative breast cancer tissues, and also breast cancer cell lines (BCC). Then BCC will be subjected to estrogens and different antiestrogens to determine their responses, and their effects and analyzed for their potential therapeutic effects. We hypothesize that ERß will eventually play an important role in controlling growth of breast cancers. We believe that ERb isoforms may be new potential therapeutic targets to the patients with non-responder to the current available ERa targeted antiestrogen therapy, and also ERa negative breast cancers who have not received the benefit of the current antiestrogen therapy.

Medical Subject Headings (MeSH)

Breast Neoplasms; Estrogen Receptor alpha; Medical Laboratory Science; Pathology; Selective Estrogen Receptor Modulators

Research at a Glance

Yale Co-Authors

Frequent collaborators of Young Choi's published research.

Publications

2024

2021

2018

2011

2010

  • ERß1, AIB-1 and TIF-2 expression in breast cancer-associated myofibroblasts.
    Choi Y. ERß1, AIB-1 and TIF-2 expression in breast cancer-associated myofibroblasts. Modern Pathol 2010; 23:40A.
    Peer-Reviewed Original Research

2009

  • Tissue –specific expression of estrogen receptor-ß wild type and its isoforms.
    Choi Y. Tissue –specific expression of estrogen receptor-ß wild type and its isoforms. Arch Pathol Lab Med 2009; 133:1632.
    Peer-Reviewed Original Research

2008

Academic Achievements & Community Involvement

  • activity

    Seoul National Medical College Alumni Association

  • activity

    College of Pathologists

  • activity

    American Society of Clinical Pathologists

Get In Touch

Contacts

Academic Office Number
Office Fax Number

Locations